Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guanfacine-ER for Cannabis Use Disorder
NCT05273567Phase 2Completed
- Sponsor
- New York State Psychiatric Institute
- Start
- Jun 2022
- Primary completion
- Sep 2023
- Countries
- 1
01
Overview
A Phase 2 trial of guanfacine in cannabis use disorder (CUD), sponsored by New York State Psychiatric Institute. Started Jun 2022; status: completed.
02
Drugs
guanfacine
03
Conditions
cannabis use disorder (CUD)
Beyond the preview
Go deeper on NCT05273567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05273567.